Parabilis Medicines cannot currently be evaluated on price-based measures due to a missing price feed, and the available fundamentals point to margin compression, insider selling, and below-average quality that argue for caution once trading data is restored.
Thesis pillars
- Value Trap Signals Margin And Insider Selling↓Deteriorating
- Data Outage Blocks Trade Setup↓Deteriorating
- Quality Concerns Flagged→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026
Parabilis Medicines, Inc. (PBLS) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.17: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.62; Below-average business quality.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that... Read more
Sell if holding. Engine safety override at $28.17: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.62; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Parabilis Medicines, Inc.
Latest news
- NEWS Parabilis Medicines Announced At ESMO Saturday, Zolucatetide Data Showing 72.2% Response Rate, 100% Disease Control At ≥ — benzinga Oct 25, 2026 positive
- NEWS Parabilis Medicines Announces Updated Phase 1/2 Data for Zolucatetide in Desmoid Tumors — fiscal.ai Oct 24, 2026 positive
- NEWS Parabilis Medicines, Inc. Initiated at Buy by HC Wainwright & Co. — fiscal.ai Oct 22, 2026 positive
- NEWS HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40 — benzinga Oct 22, 2026 positive
- NEWS Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday — benzinga Oct 19, 2026 neutral
Generated 2026-10-29T10:28:32Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.17: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 1.9:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.62; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $26.20. Score 5.8/10, moderate confidence.
Analyst target: $36.02 (+27.9% upside). Prior stop was $26.20. Stop-loss: $26.20.
Quality below floor (3.0 < 4.0).
Parabilis Medicines, Inc. trades at a P/E of N/A (forward -12.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
11 analysts cover PBLS with a consensus score of 4.4/5. Average price target: $41.
What does Parabilis Medicines, Inc. do?Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide...
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.